Not Yet RecruitingPhase 2

A Pragmatic Clinical Trial to Prevent Relapse for Myeloid Malignancies With Measurable Disease Prior to Allogeneic Transplant

United States450 participantsStarted 2026-08-01

Plain-language summary

This is a prospective, open-label investigation to determine whether measurable residual disease (MRD) guided assignment of maintenance therapy is effective in patients with myeloid malignancies undergoing allogeneic hematopoietic cell transplantation (HCT). Pre-HCT, patients will undergo usual disease assessments which should include immunophenotypic and/or molecular testing. Based on the results of these tests, patients may or may not be recommended to receive maintenance therapy post-transplant, depending on the presence or absence of a residual malignant clone.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Age ≥18 years at time of transplant.
✓. Must have a diagnosis of a myeloid malignancy, myelodysplastic syndrome, myeloproliferative neoplasm (including primary or secondary myelofibrosis), or acute myeloid leukemia or biphenotypic acute leukemia.
✓. Pre-transplant disease assessment must include at least one:
✓. Ability to understand a written informed consent document, and the willingness to sign it.

What they're measuring

Number of subjects with relapse-free survival

Timeframe: One Year

Trial details

NCT IDNCT07572929

SponsorMedical College of Wisconsin

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2034-02-01

Contact for this trial

Medical College of Wisconsin Cancer Center Clinical Trials Office

866-680-0505 cccto@mcw.edu

View on ClinicalTrials.gov More Myeloid Disorders trials